Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Area of Science:

• Regenerative Medicine
• Transplantation Biology
• Health Economics

Background:

• Current beta cell replacement therapy for type 1 diabetes faces challenges with donor-derived tissue.
• Stem cell-derived grafts present a potential solution to overcome these limitations.

Purpose of the Study:

• To investigate the cost-effectiveness of a novel stem cell-derived graft and implant technology.
• To compare this technology against intensive insulin therapy for type 1 diabetes treatment.

Main Methods:

• A manufacturing optimization model was used to estimate stem cell-based transplant costs.
• A cost-effectiveness model integrated these costs, comparing the new technology to intensive insulin therapy.
• The study considered retrievable subcutaneous implants protecting pancreatic progenitor cells and evaluated different cell culture and production scenarios.

Main Results:

• The study determined the likely cost range for stem cell-based beta cell replacement therapy.
• This technology shows potential cost-effectiveness compared to intensive insulin therapy at a $100,000 per quality-adjusted life year threshold.
• Mass production emerged as the most viable strategy for affordable graft tissue, with significant potential for overall cost reduction.

Conclusions:

• Stem cell-based implants can enhance treatment access and patient quality of life by increasing graft supply and protection.
• This innovative approach offers a feasible treatment option for a broad spectrum of type 1 diabetes patients.